Showing results (1-10 of 3,492) with videos related to

Sort By:
Pageof 350
Journal of Cancer Research and Clinical Oncology|June 14, 2022
Does first-line immunotherapy impact the efficacy of later treatments: a discussion on the use of second progression-free survival as a research endpointZhening Zhang, Lin Shen, Zhi Peng
Cancer Biology & Medicine|May 10, 2024
Advances in MET tyrosine kinase inhibitors in gastric cancerYifan Zhang, Lin Shen, Zhi Peng
Chinese Clinical Oncology|July 21, 2023
Next stage of collaboration in East Asia gastric cancer treatmentTong Xie, Zhening Zhang, Zhi Peng, et al.
Pancreas|June 17, 2020
Patients With Acinar Cell Carcinoma of the Pancreas After 2005: A Large Population StudyYuan Zong, Changsong Qi, Zhi Peng, et al.
Zhonghua Wei Chang Wai Ke Za Zhi = Chinese Journal of Gastrointestinal Surgery|November 28, 2017
[Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer]Yilin Li, Zhi Peng, Xiaotian Zhang, et al.
Therapeutic Advances in Medical Oncology|February 16, 2024
Immune checkpoint inhibitors or anti-claudin 18.2 antibodies? A network meta-analysis for the optimized first-line therapy of HER2-negative gastric cancerZhening Zhang, Tong Xie, Yingxuan Wang, et al.
International Journal of Colorectal Disease|December 19, 2019
Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?Qi Zhang, Qianqian Wang, Xicheng Wang, et al.
Annals of Palliative Medicine|June 22, 2021
Response to the rechallenge of combination immunotherapy in a patient with late-stage gastric cancer: case reportZhening Zhang, Siyuan Cheng, Changsong Qi, et al.
Cancer Management and Research|December 17, 2020
Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal AdenocarcinomaYuan Zong, Zhi Peng, Xicheng Wang, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|July 23, 2020
Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectivesZhening Zhang, Tong Xie, Xiaotian Zhang, et al.
Pageof 350